| scholarly article | Q13442814 |
| P2093 | author name string | Teresa Macarulla | |
| Tamara Saurí | |||
| Helena Verdaguer | |||
| P2860 | cites work | Global cancer statistics | Q22241238 |
| Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes | Q24595981 | ||
| Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer | Q24614511 | ||
| Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer | Q27851407 | ||
| Cetuximab for the treatment of colorectal cancer. | Q27851419 | ||
| K-ras mutations and benefit from cetuximab in advanced colorectal cancer. | Q27851454 | ||
| Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer | Q27851456 | ||
| DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. | Q27851466 | ||
| Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis | Q27851573 | ||
| Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial | Q27851578 | ||
| Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer | Q27852028 | ||
| Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. | Q27853216 | ||
| Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial | Q27853380 | ||
| Targeting RAS signalling pathways in cancer therapy | Q28201363 | ||
| Comprehensive molecular characterization of gastric adenocarcinoma | Q28244985 | ||
| PD-1 Blockade in Tumors with Mismatch-Repair Deficiency | Q28262647 | ||
| Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer | Q28271324 | ||
| Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer | Q28298328 | ||
| Systematic review of microsatellite instability and colorectal cancer prognosis | Q28303189 | ||
| Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study | Q28348036 | ||
| Signatures of mutational processes in human cancer | Q29547191 | ||
| Cancer statistics, 2009 | Q29547625 | ||
| Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world | Q29614969 | ||
| Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer | Q29616236 | ||
| ERBB receptors and cancer: the complexity of targeted inhibitors | Q29619520 | ||
| Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study | Q29619653 | ||
| Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. | Q33238550 | ||
| Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer | Q33586020 | ||
| Microsatellite instability as a marker of prognosis and response to therapy: a meta-analysis of colorectal cancer survival data | Q33631924 | ||
| Clinical relevance of microsatellite instability in colorectal cancer | Q33990921 | ||
| HER2 as a Prognostic Marker in Gastric Cancer - A Systematic Analysis of Data from the Literature | Q34223664 | ||
| Biologic and therapeutic role of HER2 in cancer | Q34267775 | ||
| Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704 | Q34600819 | ||
| Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial | Q34632818 | ||
| Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers | Q34663583 | ||
| Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: a pooled analysis of 6 prospective trials | Q34665177 | ||
| The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints | Q34943776 | ||
| Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer | Q35057350 | ||
| Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery | Q35583987 | ||
| Whole genomes redefine the mutational landscape of pancreatic cancer | Q35911034 | ||
| The consensus molecular subtypes of colorectal cancer | Q36258187 | ||
| The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers | Q36451732 | ||
| BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma | Q36854437 | ||
| HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target | Q37149210 | ||
| KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. | Q37330719 | ||
| High prevalence of BRCA1 and BRCA2 germline mutations with loss of heterozygosity in a series of resected pancreatic adenocarcinoma and other neoplastic lesions | Q37646439 | ||
| Upper Gastrointestinal Cancer Predisposition Syndromes | Q37785235 | ||
| Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer | Q38021384 | ||
| Metastatic colon cancer, version 3.2013: featured updates to the NCCN Guidelines | Q38081660 | ||
| Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial | Q38385410 | ||
| SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial | Q38385490 | ||
| Immunotherapy for Gastric Cancer: A Focus on Immune Checkpoints. | Q38735118 | ||
| mTOR inhibitor treatment of pancreatic cancer in a patient With Peutz-Jeghers syndrome | Q40972751 | ||
| Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas | Q41148624 | ||
| Human equilibrative nucleoside transporter 1 expression analysed by the clone SP 120 rabbit antibody is not predictive in patients with pancreatic cancer treated with adjuvant gemcitabine - Results from the CONKO-001 trial | Q41689546 | ||
| Prognostic significance of HER2 expression based on trastuzumab for gastric cancer (ToGA) criteria in gastric cancer: an updated meta-analysis | Q43479667 | ||
| The impact of resection margin status and postoperative CA19-9 levels on survival and patterns of recurrence after postoperative high-dose radiotherapy with 5-FU-based concurrent chemotherapy for resectable pancreatic cancer | Q43703053 | ||
| SPARC expression in resected pancreatic cancer patients treated with gemcitabine: results from the CONKO-001 study. | Q44088489 | ||
| Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial | Q44299542 | ||
| BRAF and KRAS mutations in colorectal hyperplastic polyps and serrated adenomas. | Q44564090 | ||
| The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. | Q45122012 | ||
| Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer | Q46233566 | ||
| Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas | Q47306076 | ||
| Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma. | Q50852180 | ||
| Human equilibrative nucleoside transporter 1 expression is a strong independent prognostic factor in UICC T3-T4 pancreatic cancer patients treated with preoperative gemcitabine-based chemoradiotherapy. | Q53146573 | ||
| Tracing origin of serrated adenomas with BRAF and KRAS mutations. | Q53619358 | ||
| Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. | Q54081321 | ||
| Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. | Q54122138 | ||
| Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation | Q56240758 | ||
| Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study | Q57152185 | ||
| RAF/RAS oncogenes and mismatch-repair status | Q57281056 | ||
| Poor Survival Associated with theBRAFV600E Mutation in Microsatellite-Stable Colon Cancers | Q60673656 | ||
| Evaluation of the utility of a radioimmunoassay for serum CA 19-9 levels in patients before and after treatment of carcinoma of the pancreas. | Q64980782 | ||
| Tumor-infiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinoma | Q74046178 | ||
| Lewis and secretor gene dosages affect CA19-9 and DU-PAN-2 serum levels in normal individuals and colorectal cancer patients | Q74150908 | ||
| Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma | Q79600998 | ||
| The prevalence of BRCA2 mutations in familial pancreatic cancer | Q79776058 | ||
| Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma | Q84391549 | ||
| The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host | Q94701599 | ||
| P433 | issue | 3 | |
| P921 | main subject | biomarker | Q864574 |
| P304 | page(s) | 405-417 | |
| P577 | publication date | 2017-06-01 | |
| P1433 | published in | Journal of gastrointestinal oncology | Q26842467 |
| P1476 | title | Predictive and prognostic biomarkers in personalized gastrointestinal cancer treatment | |
| P478 | volume | 8 |
| Q48134310 | Combination of TNM staging and pathway based risk score models in patients with gastric cancer. |
| Q58767691 | Identification of potential biomarkers in cervical cancer with combined public mRNA and miRNA expression microarray data analysis |
| Q49439117 | Profiles of differentially expressed genes and overexpression of NEBL indicates a positive prognosis in patients with colorectal cancer |
| Q92308991 | Prognostic Significance of Serum Uric Acid and Gamma-Glutamyltransferase in Patients with Advanced Gastric Cancer |
Search more.